<DOC>
	<DOCNO>NCT00006252</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy drug , fludarabine cyclophosphamide , donor peripheral blood stem cell transplant help stop growth cancer cell . It also help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . PURPOSE : This phase II trial study well fludarabine cyclophosphamide follow peripheral stem cell transplant work treat patient leukemia lymphoma .</brief_summary>
	<brief_title>Fludarabine Cyclophosphamide Followed Peripheral Stem Cell Transplant Treating Patients With Leukemia Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility fludarabine cyclophosphamide follow allogeneic peripheral blood stem cell transplantation , term 6-month treatment-related mortality , patient chronic lymphocytic leukemia , prolymphocytic leukemia , low-grade non-Hodgkin 's lymphoma , mantle cell lymphoma . - Determine 6-month 12-month probability response patient treat regimen . - Determine time disease progression patient respond regimen . - Determine percentage donor chimerism achieve patient treated regimen . - Determine risk acute chronic graft-versus-host disease patient treat regimen . - Determine toxic effect regimen patient . - Determine overall survival disease-free survival patient treat regimen . OUTLINE : This multicenter study . Patients receive fludarabine IV 30 minute day -7 -3 cyclophosphamide IV 1 2 hour day -5 -3 . Patients undergo allogeneic peripheral blood stem cell transplantation day 0-1 . Patients receive filgrastim ( G-CSF ) subcutaneously daily begin day 5 continue blood count recover . Patients sign active graft-versus host disease stable progressive disease receive donor lymphocytes IV 2 hour begin day 120 . Patients may receive total 3 infusion least 8 week apart disease remain stable progressive . Patients follow every 3 month 2 year every 6 month 5 year . PROJECTED ACCRUAL : A maximum 45 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow histologically confirm diagnosis : Chronic lymphocytic leukemia Absolute lymphocytosis great 5,000/mm^3 Morphologically mature lymphocytes less 55 % prolymphocytes Lymphocyte phenotypic expression CD19 CD5 Failed least 1 prior regimen Progressive lymphocytosis 50 % increase peripheral lymphocytosis progressive lymph node spleen enlargement ( least 25 % enlargement appearance new lymph node ) persist least 4 week despite concurrent prior drug treatment OR At least 1 follow highrisk factor first complete remission = 17p deletion = 11q deletion Unmutated VH gene status p53 mutation Prolymphocytic leukemia ( PLL ) Absolute lymphocytosis great 5,000/mm^3 Morphologically mature lymphocytes 55 % prolymphocytes Lowgrade nonHodgkin 's lymphoma Small lymphocytic lymphoma Follicular center lymphoma ( grade I II ) Diffuse ( predominately small cell type ) Marginal zone , Bcell lymphoma No transform lymphoma Failure least 1 prior regimen OR At least 3 follow risk factor : Over 60 year age Performance status great 1 LDH great normal More 1 site extranodal disease Disease stage III IV Mantle cell lymphoma Any stage Ineligible protocol CALGB59908 At least 1 prior treatment regimen At least 1 follow : Immunophenotypic expression CD5 CD19 absence CD23 Cytogenetic analysis presence ( 11 ; 14 ) Overexpression cyclin D1 Rearrangement BCL1 gene Responsive stable disease recent prior therapy Prior therapy PLL require Must HLA identical sibling ( 6/6 ) donor serologic typing ( A , B , DR ) No syngeneic donors No age restriction NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : Under 70 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Granulocyte count least 500/mm^3* Platelet count least 50,000/mm^3* NOTE : *Unless attributable disease Hepatic : Bilirubin great 3 time upper limit normal ( ULN ) * AST great 3 time ULN* NOTE : *Unless attributable disease Renal : Creatinine clearance least 40 mL/min , unless attributable disease Cardiovascular : LVEF least 30 % MUGA Pulmonary : DLCO great 40 % No symptomatic pulmonary disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No uncontrolled diabetes mellitus No active serious infection No known hypersensitivity E. coliderived product PRIOR CONCURRENT THERAPY : Biologic therapy : No prior autologous transplantation Chemotherapy : At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy Surgery : At least 4 week since prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
</DOC>